HM242-Gel vs Comparator

Venous Leg Ulcer Clinical Trial

Official title:

A PROSPECTIVE, CONTROLLED, RANDOMIZED, OPEN-LABEL PREMARKET MULTICENTER STUDY OF THE PERFORMANCE OF THE HM242-GEL VS COMPARATOR IN PATIENTS UNDER THE CONDITION OF VENOUS LEG ULCER

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04902651
• Other study ID #: OPM-G-H-2004
• Status: Terminated
• Phase: N/A
• Start date: May 21, 2021
• Est. completion date: February 16, 2022

Study information

• Verified date: May 2021
• Source: B. Braun Ltd. Centre of Excellence Infection Control
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to demonstrate that the HM242-Gel performs at least comparably to INTRASITE Gel with regard to wound healing.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 73
• Est. completion date: February 16, 2022
• Est. primary completion date: January 5, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males or females of at least 18 years at the time of enrolment

2. The legal capacity and ability to understand the nature, risks, significance and scope of the clinical trial and to determine his or her will accordingly

3. Signed form of consent, including the understanding of and willingness by the patient to participate in the clinical study and ability to comply with study procedures and study visit schedule

4. Patients must be willing to have all dressing changes performed by the wound specialist, with no treatments at home

5. Presence of at least one venous ulcer of the lower leg extending through the full thickness of the skin but not down to muscle, tendon or bone

6. Size of study ulcer = 2cm² and = 100cm² measured using the tracing method.

7. Presence of venous leg ulcer for at least 6 weeks, but not longer than 12 months

8. Ankle Brachial Pressure Index (ABI) > 0.75

9. In the case of a female patient of childbearing potential, willingness to use highly effective methods of contraception (failure rate of < 1% when used consistently and correctly);acceptable contraceptive measures in this trial are: combined pill and progestin-only pill, contraceptive patch, ring or injection, Etonogestrel implant, intrauterine device (IUD) (copper and Levonogestrel), male sterilization (vasectomy), female sterilization (abdominal, laparoscopic, hysteroscopic), or sexual abstinence.

Exclusion Criteria:

1. Patients kept in an institution due to an official or court order

2. Patients dependent on the Sponsor, Investigator or Site

3. Patients suspected of having SARS-CoV-2 infection or COVID-19 disease

4. Study ulcer judged by the Investigator to be caused by a medical condition other than venous insufficiency

5. Study ulcer with signs and symptoms of infection, or under suspicion of cancer

6. Study ulcer under treatment with topical antimicrobials within past two weeks or systemic antimicrobial treatment within past two weeks

7. In the case of heavily exuding ulcers, if in the opinion of Investigator the patient is not suitable for treatment with gel

8. More than two venous leg ulcers or more than two chronic wounds

9. Dementia stage greater than 3 according to Reisberg

10. Known allergies against wound dressings used in the study

11. Known chronical skin diseases, dermatoses, or known allergies or other conditions which might trigger dermatitis

12. Acute cases of substance use disorders (ICD-10 F1x.1 or F1x.2)

13. Buerger's disease

14. Participation in Medical Device trials less than 4 weeks ago or participation in Drug trials less than six months ago

15. Terminally ill patients

16. Patients with poorly managed diabetes mellitus: absence of a glycated hemoglobin test within the last 3 months or a result of HbA1c = 8% not older than 3 months, or a major diabetes-related incident within the past 4 weeks

17. Ulcers of diabetic origin

18. Patients under treatment with systemic corticosteroids, immunosuppressant, cytotoxic chemotherapy, or radiotherapy

19. Presence of one or more medical conditions (other than venous insufficiency and

diabetes) as determined by medical history, which:

• Is known to interfere with the wound healing process (e.g. arteriopathy, vasculitis, rheumatoid arthritis, systemic lupus erythematosus, other auto-immune diseases, cancer, immunodeficiency, severe lymphedema of the leg, thrombophilia)
• In the opinion of the Investigator, would make the patient an inappropriate candidate for this venous ulcer healing study (e.g. malnutrition, hygiene, obesity)

20. Pregnant or lactating patients

Related Conditions & MeSH terms

• Leg Ulcer
• Varicose Ulcer
• Venous Leg Ulcer

Intervention

Device:
• HM242-Gel
HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
• Intrasite Gel
HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer

Locations

Country	Name	City	State
Czechia	Kožní ambulance Fialová, s.r.o.	Praha	Praha 6
Slovakia	Viliam Cibik	Pruské
Slovakia	Rudolf Suchy	Trencín

Sponsors (1)

Lead Sponsor	Collaborator
B. Braun Ltd. Centre of Excellence Infection Control

Countries where clinical trial is conducted

Czechia,  Slovakia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary objective of the study is to demonstrate that the HM242-Gel performs at least comparably to INTRASITE Gel with regard to wound healing.	The primary variable is defined as the relative reduction of the wound area of a patient in percentage 28 days (4 weeks) after baseline. The wound size area is measured on site by the tracing method.	28 days